This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
cd20
CD20
B-lymphocyte surface antigen (MS4A1); expressed on pre-B through memory B cells; absent on plasma cells. Targeted by anti-CD20 monoclonal antibodies (rituximab, obinutuzumab); R-CHOP is frontline for DLBCL; CD20-negative escape post-rituximab is a resistance mechanism in NHL.
Entry Metadata
| Field | Value |
|---|---|
| ID | cd20 |
| Name | CD20 |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 03-molecular |
Cross-Atlas Connections
Sources
- Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90(6):2188-2195. · PubMed 9310469
- Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242. · PubMed 11807147